by EpicentRx | Mar 8, 2023 | Blog
In a TV review about a serial killer, we came across this pithy phrase: “all killer, no filler” (AKNF). AKNF denotes no extraneous content i.e., no filler, which perfectly encapsulates the minimalist design and effectiveness of the oncolytic adenovirus, AdAPT-001....
by EpicentRx | Mar 2, 2023 | Blog
“Anergy” is a commonly used term in immuno-oncology, particularly in conjunction with T cells. So, what exactly does it mean and in what context is it used? The dictionary defines it as the “absence of the normal immune response to a particular antigen or allergen.” A...
by EpicentRx | Mar 2, 2023 | Meet The Team
Fun facts: Main passions: surfing, Hawaii, drug development Role model: Ezekiel Lau, Hawaiian surfer Sedentary hobby: Playing in the fantasy surfing league We all know and refer to him as Mr. Don’t Worry Be Happy, Mr. San Diego Surfer, and Mr. Sunshine. This is...
by EpicentRx | Mar 1, 2023 | Conferences
March 2023, Denver Colorado Poster: TRIAL-IN-PROGRESS BETA-PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors (NCT04673942) Poster: Low dose but not high dose RRx-001...
by EpicentRx | Feb 16, 2023 | Conferences
February 2023, San Francisco, California Poster: Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors
